Newsfeeds - Spark Newswire

2 minute read

Graphite Bio Announces Voluntary Pause Of Phase 1/2 CEDAR Study Of nulabeglogene autogedtemcel For Sickle Cell Disease

Today, 1:30 PM

Graphite Bio, Inc. (NASDAQ:GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first

GRPH

2 minute read

Graphite Bio Presented Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at ASH 2022

By Charles Gross

Today, 1:30 PM

Graphite Bio, Inc.

GRPH

1 minute read

News

5 Value Stocks To Watch In The Healthcare Sector

By Benzinga Insights

Today, 1:30 PM

What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

BXRX

1 minute read

Cantor Fitzgerald Initiates Coverage On Graphite Bio with Overweight Rating, Announces Price Target of $12

By Benzinga Newsdesk

Today, 1:30 PM

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Graphite Bio (NASDAQ:GRPH) with a Overweight rating and announces Price Target of $12.

GRPH

1 minute read

News

5 Value Stocks In The Healthcare Sector

By Benzinga Insights

Today, 1:30 PM

AVTE

3 minute read

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 1:30 PM

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…

ALXO

1 minute read

Graphite Bio Files For Mixed-Securities Shelf Offering Of Up To $300M

By Michael Horton

Today, 1:30 PM

-Reuters

GRPH

1 minute read

BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

By Vandana Singh

Today, 1:30 PM

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ:GRPH), with a price target of $12 and an Outperform rating. The analyst…

GRPH

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 17, 2022

By Benzinga Insights

Today, 1:30 PM

Upgrades

ACHC

2 minute read

Analyst Ratings

Where Graphite Bio Stands With Analysts

By Benzinga Insights

Today, 1:30 PM

Over the past 3 months, 5 analysts have published their opinion on Graphite Bio (NASDAQ:GRPH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

GRPH